MAR 08, 2016 1:19 PM PST

New drug blows up malaria parasites in blood

Malaria killed about 440,000 people—mostly young children—last year, but a new drug candidate may help fight the disease.

"The thing about malaria is that really, really poor people have it, so the medicine has to be very inexpensive," says Spencer Knapp. "We think that ours is going to be inexpensive." Above: Mohammed, suffering from Malaria, recovers at a Burundian run clinic in Somalia's capital, Mogadishu.

Scientists are now ready to test the compound, which literally blows up malaria parasites in the blood stream, in people, says Spencer Knapp, a chemistry professor at Rutgers University.

“That’s actually a very exciting development. The drugs that are out there are starting to encounter resistance, so this is a new drug candidate just now entering trials. We don’t know how effective it will be yet in humans.”

The compound, code-named SJ733, works in a new way, says Knapp, who first prepared the chemical in his lab. It binds to a malaria parasite protein that serves as a sodium (salt) pump. The pump is designed to get rid of sodium, but the compound blocks or interferes with the protein, and sodium ions build up. That allows water to rush in, blowing up the parasite inside human blood cells.

Malaria, a mosquito-borne disease, can make people very sick. Fever, chills, and flu-like illness are common symptoms, according to the US Centers for Disease Control and Prevention. More severe cases of malaria can lead to seizures, coma, severe anemia, acute respiratory distress, kidney failure, and other problems.

The United States was deemed malaria-free in 1949, according to the CDC. But last year, an estimated 214 million people worldwide contracted malaria, according to the World Health Organization. The scourge is particularly lethal to children under five, who accounted for 70 percent of the roughly 440,000 deaths.

Africa is essentially ground-zero for malaria. Last year, 88 percent of malaria cases and 90 percent of deaths linked to the disease were there.

The good new is malaria cases and deaths have dropped significantly in recent years. Between 2000 and 2015, new malaria cases fell 37 percent globally and 42 percent in Africa. Malaria death rates plunged by 60 percent globally and 66 percent in Africa.

Three key reasons are greater use of insecticide-treated mosquito nets, indoor spraying and artemisinin-based combination therapies. The latter medicines are very effective against P. falciparum, the deadliest and most common malaria parasite.

Large amounts of SJ733—4 kilograms or 8.8 pounds—were  synthesized by contract for the clinical trials. The compound has been tested successfully in preclinical safety studies, with no side effects detected so far.  “There are plenty of compounds that don’t make it through animal studies, but ours has made it through,” Knapp says.

The clinical trials could last as long as two years. During phase 1, SJ733—in the form of pills—will be given to healthy volunteers to assess the safety and pharmacokinetics of the compound. Pharmacokinetics are how drugs are absorbed, distributed, metabolized and eliminated by the body.

Then SJ733 would be tested in two phases of human malaria studies to find out if it works and if it’s safe.

“The thing about malaria is that really, really poor people have it, so the medicine has to be very inexpensive,” Knapp says. “We think that ours is going to be inexpensive.”

Rutgers is co-holder, with St. Jude Children’s Research Hospital in Memphis, Tennessee, and Medicines for Malaria Venture in Geneva, of a pending US patent.

Source: Rutgers University

This article was originally published on futurity.org.
About the Author
  • Futurity features the latest discoveries by scientists at top research universities in the US, UK, Canada, Europe, Asia, and Australia. The nonprofit site, which launched in 2009, is supported solely by its university partners (listed below) in an effort to share research news directly with the public.
You May Also Like
NOV 20, 2020
Neuroscience
The Link Between Sleep Apnea and Autoimmune Disease
NOV 20, 2020
The Link Between Sleep Apnea and Autoimmune Disease
Researchers from the University of Georgia have found more evidence for the link between obstructive sleep apnea (OSA) a ...
FEB 18, 2021
Cardiology
Ongoing Heart Problems in Discharged COVID-19 Patients
FEB 18, 2021
Ongoing Heart Problems in Discharged COVID-19 Patients
About 50 percent of patients that are discharged from the hospital after recovering from a severe case of COVID-19 who e ...
MAR 30, 2021
Cardiology
Looking at a Fertility Drug's Cardiac Safety
MAR 30, 2021
Looking at a Fertility Drug's Cardiac Safety
New drugs go through a long and arduous process before they can grace a doctor’s office. One of the last steps is ...
APR 27, 2021
Cardiology
Excess Belly Weight Raises Heart Disease Risk Regardless of BMI
APR 27, 2021
Excess Belly Weight Raises Heart Disease Risk Regardless of BMI
Research has suggested that excess weight around the midsection of a person's body is a much better predictor of poor he ...
MAY 04, 2021
Cardiology
Does Sleep Apnea Affect Blood Pressure During REM Sleep?
MAY 04, 2021
Does Sleep Apnea Affect Blood Pressure During REM Sleep?
Sleep is a time for your body to rest and recover from the day. Your heart slows down, and your breathing relaxes.   ...
MAY 12, 2021
Cannabis Sciences
Cannabis Users with Heart Disorders More Likely to Die in Hospital
MAY 12, 2021
Cannabis Users with Heart Disorders More Likely to Die in Hospital
Researchers have found that hospitalized cannabis users with arrhythmia, a heart rhythm disorder, are 4.5 times more lik ...
Loading Comments...